Patterson Sandra 4
4 · GILEAD SCIENCES, INC. · Filed Dec 16, 2024
Insider Transaction Report
Form 4
Patterson Sandra
SVP, Controllership
Transactions
- Exercise/Conversion
Restricted Stock Unit
2023-12-13−181→ 12,101 total→ Common Stock (181 underlying) - Exercise/Conversion
Common Stock
2023-12-13+117→ 37,376 total - Tax Payment
Common Stock
2023-12-13$83.09/sh−298$24,761→ 37,235 total - Exercise/Conversion
Restricted Stock Unit
2023-12-13−117→ 11,984 total→ Common Stock (117 underlying) - Exercise/Conversion
Restricted Stock Unit
2024-12-13−157→ 11,827 total→ Common Stock (157 underlying) - Tax Payment
Common Stock
2024-12-13$91.86/sh−157$14,421→ 37,078 total - Exercise/Conversion
Common Stock
2023-12-13+181→ 37,259 total - Exercise/Conversion
Common Stock
2024-12-13+157→ 37,533 total
Footnotes (4)
- [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- [F2]Mandatory tax withholding on vesting of restricted stock units due to retirement eligibility.
- [F3]The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.
- [F4]The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.